Universitätsklinikum Ulm

Real-world outcomes using PD-1 antibodies and BRAF plus MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland (2022) Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akcetin L, et al. Journal article Diaphyseal Femur Fractures in Children and Adolescents-Opportunities and Limitations of the ESIN Technique (2022) Kalbitz M, Fischer A, Weber B, Mayer B, Lackner I, Preßmar J Journal article Sarcoma of the UterusGuideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021) (2022) Denschlag D, Ackermann S, Battista MJ, Cremer W, Egerer G, Fehr M, Follmann M, et al. Journal article A genome-wide association study with tissue transcriptomics identifies genetic drivers for classic bladder exstrophy (2022) Mingardo E, Beaman G, Grote P, Nordenskjöld A, Newman W, Woolf AS, Eckstein M, et al. Journal article Adipose cells and tissues soften with lipid accumulation while in diabetes adipose tissue stiffens (2022) Abuhattum S, Kotzbeck P, Schlüßler R, Harger A, Ariza de Schellenberger A, Kim K, Escolano JC, et al. Journal article UEG position paper: Obesity and digestive health (2022) Burra P, Arvanitakis M, Dias JA, Bretthauer M, Dugic A, Hartmann D, Michl P, et al. Journal article Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, Crysandt M, et al. Conference contribution Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma (2022) Straka C, Schaefer-Eckart K, Hertenstein B, Bassermann F, Salwender H, Langer C, Kroenke J, et al. Conference contribution Outcome of 841 Older Patients (> 55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols (2022) Goekbuget N, Viardot A, Steffen B, Hahn J, Spriewald B, Martin S, Raffel S, et al. Conference contribution Early CRP kinetics predict long-term treatment success and favorable outcomes of anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma (2022) Klümper N, Sikic D, Saal J, Buettner T, Jarczyk J, Zeuschner P, Weinke M, et al. Conference contribution